ONCY (Oncolytics Biotech) ROCE %: -1,759.85% (As of Mar. 2026)


ONCY Oncolytics Biotech Inc ONCY
31 GF Score
Price $0.92
! 2 Warning Signs
View Full Analysis

What is Oncolytics Biotech ROCE %?

Oncolytics Biotech ONCY -0.98% 31 ROCE % is -1,759.85% as of Mar. 2026. GuruFocus rates ONCY with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Oncolytics Biotech's annualized ROCE % for the quarter that ended in Mar. 2026 was -1,759.85%.

Oncolytics Biotech  (NAS:ONCY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Oncolytics Biotech ROCE % Related Terms

Oncolytics Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Oncolytics Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncolytics Biotech ROCE % Chart

Oncolytics Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -70.13 -67.85 -100.54 -147.62 -573.53

Oncolytics Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -219.82 -170.72 -526.03 -1,135.53 -1,759.85
ONCY
31GF Score
Oncolytics Biotech Inc ONCY
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oncolytics Biotech ROCE % Calculation

Oncolytics Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-28.725/( ( (13.421 - 4.885) + (7.582 - 6.101) )/ 2 )
=-28.725/( (8.536+1.481)/ 2 )
=-28.725/5.0085
=-573.53 %

Oncolytics Biotech's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-37.124/( ( (7.582 - 6.101) + (8.161 - 5.423) )/ 2 )
=-37.124/( ( 1.481 + 2.738 )/ 2 )
=-37.124/2.1095
=-1,759.85 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -1,759.85% mean?
Oncolytics Biotech (ONCY) has a ROCE % of -1,759.85% as of Mar. 2026.
Is Oncolytics Biotech's ROCE % too high?
Oncolytics Biotech's current ROCE % is -1,759.85%. Overall, Oncolytics Biotech has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oncolytics Biotech's ROCE % compare to ALPS and KLRS?
Oncolytics Biotech's ROCE % of -1,759.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Oncolytics Biotech's current ROCE % is -1,759.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolytics Biotech stock overvalued right now?
Oncolytics Biotech (ONCY) has a current ROCE % of -1,759.85%. The current ROCE % is -1,759.85%. Oncolytics Biotech's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Oncolytics Biotech (ONCY), the current ROCE % is -1,759.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oncolytics Biotech Business Description

Address 4350 Executive Drive, Suite 325, San Diego, CA, USA, 92121
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
31GF Score

Get the complete analysis for ONCY

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.92
Price